$UNH

Parkev Tatevosian, CFA on $UNH (Nov 11, 2026)

AI summary · Parkev Tatevosian, CFA

UNH remains a buying opportunity: it is recovering from 2025 cost mispricing, long-term EPS growth estimates have rebounded to over 14.2% within management's 13-16% target, and high costs persist, with market exits and price increases reducing customers. At a forward P/E of 17, below pre-2025 levels and near long-term EPS growth, and with a DCF value of $532 versus $396 now, it looks undervalued; risk-reward is worthwhile though no stock is risk-free.

BullishHe framed it in years
“Is it Too Late to Buy UnitedHealth Stock? | UNH Stock Analysis”
Parkev Tatevosian, CFAPublished Nov 11 · 15 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

15 passages
0:005:20

UnitedHealth Group is recovering from the enormous difficulties it faced in 2025. Remember that in that year, the company underestimated the cost of serving its customers and therefore did not price its policies appropriately, resulting in a significant decrease in the company's profitability and free cash flow .

The share price fell sharply, and the management team informed investors that we would be making adjustments starting in 2026 and things would improve, and this has turned out to be the case so far this year.

So, a shout-out to the management team . In fact, things went a little better than the management team had expected. So this was very positive, and the stock price responded to it .

It has risen by nearly 20% since the beginning of the year in 2026, and I am happy about that because I rated it as a buying opportunity.

So I wanted to reassess the company, to see if it was still a buying opportunity now in November, or if the share price had risen so high that it was no longer an attractive position.

An interesting fact is that UnitedHealth Group has almost convinced Wall Street of its long-term earnings growth prospects, hasn't it? Last year, when she was going through her challenges, she was telling Wall Street analysts that we believe in the long run that we can increase earnings per share by 13 to 16% for several consecutive years. We believe we can do that consistently.

At that time, Wall Street analysts were saying, "No, we don't think you can do that," and you can see that reflected in earnings per share growth estimates that have collapsed to a flat or negative level, can't you ?

Therefore, Wall Street analysts were not confident that UnitedHealth Group could truly achieve double-digit earnings per share growth for the next few years.

But you can see that the situation has changed here in 2026. Look how quickly the earnings per share estimates have been revised upwards, and they are now back to over 14.2%, which is exactly in the middle of the management team’s estimates of between 13 and 16%.

So they have almost completely convinced investors of their ability to deliver the long-term growth they suggested they could achieve, a point they reaffirmed two weeks ago when they held a meeting with Wall Street analysts .

They said: "From 13 to 16%, we are still confident in our ability to reach this goal."

So in 2026, they were also able to use some of the cash flow the company had generated to pay off some of the debt. They started the year with about $80 billion of total long-term debt, and now have just over $71.4 billion of long- term debt.

This represents a reduction of about $9 billion , or slightly more than 10% of their long-term debt, which should reduce interest expenses, increase free cash flow , and give the management team more liquidity to pay down more debt or repurchase shares, which they have been doing aggressively over the past 12 to 18 months.

The rating improved, but not significantly. UnitedHealth stock is now trading at a forward P/E ratio of 17, which is still lower than it was before the 2025 difficulties.

I think that's partly because the structural increases in costs are still there, right? So, it's not as you know, one of the reasons the management team faced difficulties in 2025 was that they underestimated the high costs of customer service.

So in 2026, they estimated the cost of customer service more accurately. Costs did not decrease , but the management team became more capable of estimating those costs, so they did not underestimate them .

Therefore, they were able to make business decisions that better reflected the high-cost environment . However, high costs continue to negatively impact the business. They have selectively chosen to exit certain markets and raise pricing policies, ultimately resulting in a decrease in the number of customers being served.

So , this is still partially present and causing some concern for investors, and therefore the valuation is still relatively low compared to pre- 2025 levels at a forward P/E ratio of 17.

But I think this is an attractive valuation because it is very close to the company’s long-term earnings per share growth estimates of 13% to 16%. So today I also updated my discounted cash flow assessment for UnitedHealth Group , and calculated that the company is worth $532 per share. The current market price is $396 per share.

Therefore, whether you look at it based on the forward price-to-earnings ratio or using a discounted cash flow model, the stock appears to be undervalued. To answer the question I posed in the introduction, I still believe that the stock represents a buying opportunity. I confirmed that through my ranking today.

But of course, no stock is risk-free. There are always risks involved, but I believe the risk-reward ratio is worthwhile in this situation.

What this channel has said about $UNH

Parkev Tatevosian, CFA has 2 calls on this stock; only the adjacent ones are shown.

TickerSays